EvaluatePharma has totted up the figures for R&D spend and costs for biopharmas, and the figures are huge.

Cell Medica has bought Catapult Therapy TCR for its clinical-phase WT1 T-cell receptor cell therapy.

Seattle Genetics has called a halt to all clinical testing of vadastuximab talirine (SGN-CD33A) after seeing a higher rate of patient deaths with the drug in a…

Gamida Cell has upped its financing by $40 million in its latest funding round to prep for final work on a late-stage stem cell blood cancer therapy.

An Ernst & Young report shows a mixed bag across the whole sector.

J&J has unveiled another clutch of deals and collaborations with industry and academia.

GlaxoSmithKline, Dupont and Bristol-Myers Squibb vet Douglas Manion, M.D., FRCP(C), has become the new CEO of Kleo Pharmaceuticals.

Following a major reorganization earlier this year that saw it sell off its marketed med and revert back to being a clinical-stage biotech, Merrimack is making…

Eli Lilly is paying $55 million upfront for the rights to KeyBioscience’s pipeline of treatments for Type 2 diabetes and other metabolic conditions.

Roche is axing work on IDO med indoximod and handing back the rights to partner NewLink Genetics.